Telisotuzumab vedotin（Cat No.:I041197）is an investigational antibody-drug conjugate (ADC) designed for the treatment of cancers, particularly non-small cell lung cancer (NSCLC) that overexpresses the c-Met receptor. The drug combines an anti-c-Met monoclonal antibody with a potent chemotherapy agent, MMAE, which is delivered directly to cancer cells upon binding to c-Met. This targeted approach allows for precise tumor cell destruction while minimizing damage to healthy tissues. Ongoing clinical trials are assessing its safety, efficacy, and potential as a targeted therapy for patients with c-Met-positive cancers, especially NSCLC.
